These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 27326766)

  • 1. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23.
    Dahlerup JF; Jacobsen BA; van der Woude J; Bark LÅ; Thomsen LL; Lindgren S
    Scand J Gastroenterol; 2016 Nov; 51(11):1332-8. PubMed ID: 27326766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice.
    Stein J; Walper A; Klemm W; Farrag K; Aksan A; Dignass A
    Scand J Gastroenterol; 2018 Sep; 53(9):1059-1065. PubMed ID: 30222479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease.
    Reinisch W; Altorjay I; Zsigmond F; Primas C; Vogelsang H; Novacek G; Reinisch S; Thomsen LL
    Scand J Gastroenterol; 2015; 50(10):1226-33. PubMed ID: 25900645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).
    Reinisch W; Staun M; Tandon RK; Altorjay I; Thillainayagam AV; Gratzer C; Nijhawan S; Thomsen LL
    Am J Gastroenterol; 2013 Dec; 108(12):1877-88. PubMed ID: 24145678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia.
    Derman R; Roman E; Modiano MR; Achebe MM; Thomsen LL; Auerbach M
    Am J Hematol; 2017 Mar; 92(3):286-291. PubMed ID: 28052413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.
    Bhandari S; Kalra PA; Berkowitz M; Belo D; Thomsen LL; Wolf M
    Nephrol Dial Transplant; 2021 Jan; 36(1):111-120. PubMed ID: 32049331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
    Birgegård G; Henry D; Glaspy J; Chopra R; Thomsen LL; Auerbach M
    Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
    Pollock RF; Muduma G
    Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease.
    Nordfjeld K; Andreasen H; Thomsen LL
    Drug Des Devel Ther; 2012; 6():43-51. PubMed ID: 22419860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
    Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
    J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
    JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial.
    Gybel-Brask M; Seeberg J; Thomsen LL; Johansson PI
    Transfusion; 2018 Apr; 58(4):974-981. PubMed ID: 29424441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial.
    Auerbach M; Henry D; Derman RJ; Achebe MM; Thomsen LL; Glaspy J
    Am J Hematol; 2019 Sep; 94(9):1007-1014. PubMed ID: 31243803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice.
    Stein J; Aksan A; Klemm W; Nip K; Weber-Mangal S; Dignass A
    J Crohns Colitis; 2018 Jun; 12(7):826-834. PubMed ID: 29955835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer
    Mulder MB; van den Hoek HL; Birnie E; van Tilburg AJP; Westerman EM
    Br J Clin Pharmacol; 2019 Feb; 85(2):385-392. PubMed ID: 30393904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.
    Bhandari S; Kalra PA; Kothari J; Ambühl PM; Christensen JH; Essaian AM; Thomsen LL; Macdougall IC; Coyne DW
    Nephrol Dial Transplant; 2015 Sep; 30(9):1577-89. PubMed ID: 25925701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.
    Kalra PA; Bhandari S; Saxena S; Agarwal D; Wirtz G; Kletzmayr J; Thomsen LL; Coyne DW
    Nephrol Dial Transplant; 2016 Apr; 31(4):646-55. PubMed ID: 26250435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
    Ziedan A; Bhandari S
    Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia.
    Cococcioni L; Pensabene L; El-Khouly S; Chadokufa S; McCartney S; Saliakellis E; Kiparissi F; Borrelli O
    Dig Liver Dis; 2021 Jul; 53(7):830-834. PubMed ID: 33775573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.